Market Cap (In EUR)
17.66 Million
Revenue (In EUR)
1.32 Million
Net Income (In EUR)
-23.48 Million
Avg. Volume
21.00
- Currency
- EUR
- Country
- Healthcare
- Open
- -
- Prev. Close
- -
- Day Range
- -
- Year Range
- 1.758-11.02
- PE
- -
- EPS
- -
- Beta Value
- 1.824
- ISIN
- FR001400K4B1
- CUSIP
- -
- CIK
- -
- Shares
- -
- Earnings Annoncement
- -
Company Profile
- Sector
- Healthcare
- Industry
- Medical - Pharmaceuticals
- CEO
- Mr. Thibaut du Fayet
- Employee Count
- -
- Website
- https://www.erytech.com
- Ipo Date
- 2014-09-19
- Details
- ERYTECH Pharma S.A., a clinical-stage biopharmaceutical company, develops red blood cell-based therapeutics for cancer and orphan diseases in France and the United States. Its lead product candidate is eryaspase, which is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in Phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. The company also engages in developing erymethionase, a preclinical product candidate that consists of methionine-?-lyase in red blood cells to target methionine cancers. The company was incorporated in 2004 and is headquartered in Lyon, France.
More Stocks
-
YUMC
-
BMAX
-
FTZFertoz Limited
FTZ
-
CBRE
-
KAMART
-
GSPGas Plus S.p.A.
GSP
-
0R7TTINC NV
0R7T
-
GCL